Equities analysts expect that TherapeuticsMD Inc (NASDAQ:TXMD) will report $4.59 million in sales for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for TherapeuticsMD’s earnings. The highest sales estimate is $5.09 million and the lowest is $4.22 million. TherapeuticsMD reported sales of $4.42 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 3.8%. The company is scheduled to announce its next earnings report on Monday, November 5th.

On average, analysts expect that TherapeuticsMD will report full-year sales of $19.06 million for the current financial year, with estimates ranging from $17.47 million to $20.70 million. For the next fiscal year, analysts expect that the firm will post sales of $128.64 million per share, with estimates ranging from $74.00 million to $180.20 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for TherapeuticsMD.

TherapeuticsMD (NASDAQ:TXMD) last issued its quarterly earnings data on Monday, July 30th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.03). The firm had revenue of $3.80 million for the quarter, compared to analysts’ expectations of $4.23 million. TherapeuticsMD had a negative net margin of 582.86% and a negative return on equity of 80.75%. TherapeuticsMD’s revenue was down 11.6% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.10) EPS.

TXMD has been the subject of a number of research reports. ValuEngine cut shares of TherapeuticsMD from a “buy” rating to a “hold” rating in a research note on Friday, June 1st. Cantor Fitzgerald set a $26.00 price objective on shares of TherapeuticsMD and gave the company a “buy” rating in a research note on Friday, August 10th. Oppenheimer set a $12.00 price objective on shares of TherapeuticsMD and gave the company a “buy” rating in a research note on Monday, July 30th. JPMorgan Chase & Co. started coverage on shares of TherapeuticsMD in a research note on Friday, June 15th. They issued an “overweight” rating and a $11.00 price objective for the company. Finally, Zacks Investment Research cut shares of TherapeuticsMD from a “hold” rating to a “sell” rating in a research note on Wednesday, April 25th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the company. TherapeuticsMD currently has a consensus rating of “Buy” and a consensus price target of $14.75.

Several institutional investors have recently made changes to their positions in TXMD. Cetera Advisors LLC raised its holdings in TherapeuticsMD by 18.1% during the 1st quarter. Cetera Advisors LLC now owns 57,450 shares of the company’s stock valued at $281,000 after buying an additional 8,800 shares during the last quarter. ING Groep NV raised its holdings in TherapeuticsMD by 3.4% during the 1st quarter. ING Groep NV now owns 278,138 shares of the company’s stock valued at $1,355,000 after buying an additional 9,176 shares during the last quarter. Swiss National Bank raised its holdings in TherapeuticsMD by 4.0% during the 1st quarter. Swiss National Bank now owns 301,400 shares of the company’s stock valued at $1,468,000 after buying an additional 11,600 shares during the last quarter. Iridian Asset Management LLC CT raised its holdings in TherapeuticsMD by 20.3% during the 2nd quarter. Iridian Asset Management LLC CT now owns 68,841 shares of the company’s stock valued at $430,000 after buying an additional 11,629 shares during the last quarter. Finally, OppenheimerFunds Inc. raised its holdings in TherapeuticsMD by 0.7% during the 1st quarter. OppenheimerFunds Inc. now owns 1,646,316 shares of the company’s stock valued at $8,017,000 after buying an additional 12,236 shares during the last quarter. 72.13% of the stock is owned by institutional investors.

NASDAQ:TXMD traded down $0.16 during mid-day trading on Thursday, hitting $5.39. 2,339,948 shares of the stock traded hands, compared to its average volume of 2,521,939. The stock has a market cap of $1.21 billion, a P/E ratio of -14.57 and a beta of 1.53. TherapeuticsMD has a 12-month low of $4.34 and a 12-month high of $7.66. The company has a current ratio of 7.88, a quick ratio of 7.79 and a debt-to-equity ratio of 0.94.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.

See Also: What kind of dividend yield to CEF’s pay?

Get a free copy of the Zacks research report on TherapeuticsMD (TXMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.